D J Storey1, M Sakala2, C M McLean2, H A Phillips2, L K Dawson2, L R Wall2, M T Fallon3, S Clive2. 1. Department of Palliative Care and Supportive Oncology, Institute of Genetics and Molecular Medicine, University of Edinburgh Cancer Research Centre; Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK. Electronic address: dawn.storey@ed.ac.uk. 2. Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK. 3. Department of Palliative Care and Supportive Oncology, Institute of Genetics and Molecular Medicine, University of Edinburgh Cancer Research Centre.
Abstract
BACKGROUND: There is speculation that peripheral neuropathy (PN) with capecitabine and oxaliplatin (CapOx; 130 mg/m(2), day 1, every 21 days) may be more common than with FOLFOX4 (5-fluorouracil and oxaliplatin 85 mg/m(2), day 1, every 14 days). We aimed to determine PN incidence and associations during CapOx, and 6 and 12 months after CapOx. PATIENTS AND METHODS: Retrospective audit of 188 oxaliplatin-naive colorectal cancer patients (87 adjuvant, 101 palliative) who received at least one cycle of CapOx. Neurosensory Common Toxicity Criteria Adverse Events version 3 were applied. RESULTS: Overall, 94% experienced acute PN. Worst severities for adjuvant and palliative patients, respectively, were grade 1, 44% and 54%; grade 2, 35% and 32%; grade 3, 16% and 3%; grade 4, 0% and 1% and grade unclear 1% and 1%. Two patients developed PN after CapOx completion despite no symptoms during treatment. Chronic PN at 6 months affected 57% and 18% of adjuvant and palliative patients, respectively. At 12 months, 35% and 16% were affected. Chronic PN at 12 months was associated with cumulative oxaliplatin dose but not age, gender, acute myotonia, pseudolaryngospasm or grade 2 or more PN during treatment. CONCLUSION: Incidence of acute PN during CapOx appears similar to FOLFOX4 but chronic PN in adjuvant patients may be more common with CapOx.
BACKGROUND: There is speculation that peripheral neuropathy (PN) with capecitabine and oxaliplatin (CapOx; 130 mg/m(2), day 1, every 21 days) may be more common than with FOLFOX4 (5-fluorouracil and oxaliplatin 85 mg/m(2), day 1, every 14 days). We aimed to determine PN incidence and associations during CapOx, and 6 and 12 months after CapOx. PATIENTS AND METHODS: Retrospective audit of 188 oxaliplatin-naive colorectal cancerpatients (87 adjuvant, 101 palliative) who received at least one cycle of CapOx. Neurosensory Common Toxicity Criteria Adverse Events version 3 were applied. RESULTS: Overall, 94% experienced acute PN. Worst severities for adjuvant and palliative patients, respectively, were grade 1, 44% and 54%; grade 2, 35% and 32%; grade 3, 16% and 3%; grade 4, 0% and 1% and grade unclear 1% and 1%. Two patients developed PN after CapOx completion despite no symptoms during treatment. Chronic PN at 6 months affected 57% and 18% of adjuvant and palliative patients, respectively. At 12 months, 35% and 16% were affected. Chronic PN at 12 months was associated with cumulative oxaliplatin dose but not age, gender, acute myotonia, pseudolaryngospasm or grade 2 or more PN during treatment. CONCLUSION: Incidence of acute PN during CapOx appears similar to FOLFOX4 but chronic PN in adjuvant patients may be more common with CapOx.
Authors: Christina Teng; Jordan Cohen; Sam Egger; Prunella L Blinman; Janette L Vardy Journal: Support Care Cancer Date: 2021-08-19 Impact factor: 3.603
Authors: Erika Viel; David Truong; Laurie Rambach; François Guinet; André Vanoli; Benjamin Schipman; Djamel Harami Journal: Med Acupunct Date: 2021-06-16
Authors: M T Fallon; D J Storey; A Krishan; C J Weir; R Mitchell; S M Fleetwood-Walker; A C Scott; L A Colvin Journal: Support Care Cancer Date: 2015-02-15 Impact factor: 3.603